Kurishima Koichi, Ohara Gen, Kagohashi Katsunori, Takayashiki Norio, Tamura Tomohiro, Shiozawa Toshihiro, Miyazaki Kunihiko, Kawaguchi Mio, Satoh Hiroaki, Hizawa Nobuyuki
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan.
Division of Pathology, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan.
Exp Ther Med. 2014 Oct;8(4):1267-1270. doi: 10.3892/etm.2014.1914. Epub 2014 Aug 18.
Cases of ossification and increased bone mineral density (BMD) at sites of bone metastasis following zoledronic acid (ZA) treatment have not been reported. The current study presents the case of a 65-year-old patient with lung adenocarcinoma and bone metastases in the lumbar vertebrae and femurs. Ossification and an increase in BMD at the metastatic sites was achieved following treatment with ZA and irradiation of the bone metastatic sites. The patient was able to maintain a normal lifestyle for over two years, despite the bone metastases. Therefore, as treatment with ZA was demonstrated to improve patient quality of life, physicians should consider this treatment strategy, particularly for the treatment of metastasis in weight-bearing bones.
唑来膦酸(ZA)治疗后骨转移部位出现骨化和骨矿物质密度(BMD)增加的病例尚未见报道。本研究报告了一例65岁肺腺癌患者,其腰椎和股骨发生骨转移。在使用ZA治疗并对骨转移部位进行放疗后,转移部位实现了骨化且BMD增加。尽管存在骨转移,该患者仍能够维持正常生活方式超过两年。因此,由于已证明ZA治疗可改善患者生活质量,医生应考虑这种治疗策略,尤其是用于治疗负重骨转移。